Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tambotatug pelitecan + tarlatamab
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Imdelltra + YL201 is an investigational combination therapy being evaluated for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The combination consists of Imdelltra (tarlatamab), a first-in-class bispecific T-cell engager (BiTE) targeting delta-like ligand 3 (DLL3) and CD3, and YL201 (tambotatug pelitecan), an antibody-drug conjugate (ADC) targeting B7-homologue 3 (B7-H3, CD276) conjugated to a topoisomerase I inhibitor payload via a tumor microenvironment-activable linker (TMALIN). By combining tarlatamab's ability to redirect T-cell-mediated cytotoxicity against DLL3-expressing tumor cells with YL201's targeted delivery of a cytotoxic payload to B7-H3-expressing cells and its subsequent bystander effect, the regimen aims to provide synergistic antitumor activity. The combination is being evaluated in a Phase Ib clinical trial (DeLLphi-310) led by Amgen in collaboration with MediLink Therapeutics.
- Brand names
- Imdylltra
- Other names
- Imdelltra + tambotatug pelitecanImdelltra + YL201tambotatug pelitecan + tarlatamabtarlatamab + tambotatug pelitecantarlatamab + YL201tarlatamab-dlle + YL201
02
Targets
B7-H3CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on tambotatug pelitecan + tarlatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tambotatug pelitecan + tarlatamab.